Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Sep;2(3):613-21.
doi: 10.2147/opth.s3881.

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy

J Charles Henry  1 , James H Peace, Jeanette A Stewart, William C Stewart
Affiliations
Free PMC article

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy

J Charles Henry et al. Clin Ophthalmol. 2008 Sep.
Free PMC article

Abstract

Purpose: To evaluate the efficacy, safety and tolerability of changing to travoprost BAK-free from prior prostaglandin therapy in patients with primary open-angle glaucoma or ocular hypertension.

Design: Prospective, multi-center, historical control study.

Methods: Patients treated with latanoprost or bimatoprost who needed alternative therapy due to tolerability issues were enrolled. Patients were surveyed using the Ocular Surface Disease Index (OSDI) to evaluate OSD symptoms prior to changing to travoprost BAK-free dosed once every evening. Patients were re-evaluated 3 months later.

Results: In 691 patients, travoprost BAK-free demonstrated improved mean OSDI scores compared to either latanoprost or bimatoprost (p < 0.0001). Patients having any baseline OSD symptoms (n = 235) demonstrated significant improvement after switching to travoprost BAK-free (p < 0.0001). In 70.2% of these patients, symptoms were reduced in severity by at least 1 level. After changing medications to travoprost BAK-free, mean intraocular pressure (IOP) was significantly decreased (p < 0.0001). Overall, 72.4% preferred travoprost BAK-free (p < 0.0001, travoprost BAK-free vs prior therapy). Travoprost BAK-free demonstrated less conjunctival hyperemia than either prior therapy (p < 0.0001).

Conclusions: Patients previously treated with a BAK-preserved prostaglandin analog who are changed to travoprost BAK-free have clinically and statistically significant improvement in their OSD symptoms, decreased hyperemia, and equal or better IOP control.

Keywords: benzalkonium chloride; bimatoprost; glaucoma; latanoprost; ocular surface disease; preservative; prostaglandin analog; travoprost.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Improvement in ocular surface disease index scores with travoprost BAK-free according to previous prostaglandin analog use. *p < 0.0001.
Figure 2
Figure 2
Improvement in ocular surface disease index scores with travoprost BAK-free according to baseline severity. *p < 0.0001.
Figure 3
Figure 3
Clinically significant improvement (≥9 points) in ocular surface disease index scores with travoprost BAK-free according to baseline severity.
Figure 4
Figure 4
Change in mean IOP with travoprost BAK-free according to previous prostaglandin analog use. *p < 0.0001.
Figure 5
Figure 5
Change in mean hyperemia scores with travoprost BAK-free according to previous prostaglandin analog use. *p < 0.0001.
See this image and copyright information in PMC

References

    1. Astin M, Stjernschantz J, Selén G. Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994;59:401–7. - PubMed
    1. Baudouin C, Riancho LM, Warnet JM, et al. In vitro studies of anti-glaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007;48:4123–8. - PubMed
    1. Book SA. Essentials of statistics. New York: McGraw-Hill; 1978. pp. 117–22.
    1. Epstein SP, Chen D, Asbell PA. The effect of travoprost Z, latanoprost and their individual components on the ocular surface (corneal and conjunctival epithelium). Presented at the Association for Research in Vision and Ophthalmology (ARVO); May 7, 2008; Fort Lauderdale, FL.
    1. Fechtner R, Budenz D, Godfrey D. Prevalence of ocular surface disease symptoms in glaucoma patients on IOP-lowering medications. Poster presented at: Annual meeting of the American Glaucoma Society; March 8, 2008; Washington DC. 2008.